Cocrystal Pharma COCP 深 沪
已收盘 08-01 16:00:00 美东时间
1.85
+0.120
+6.94%
华盛通- 最 高1.98
- 今 开1.765
- 成交量 204.39万股
- 最 低 1.5601
- 昨 收 1.73
- 总市值 1882.15万
- 52周最高 3.26
- 市盈率 静 --
- 换手率 20.09%
- 52周最低 1.12
- 委 比 -85.89%
- 总股本 1017.38万
- 历史最高 66.00
- 量 比 40.64
- 振 幅 24.27%
- 历史最低 1.12
- 每 手 1
- 风险率 0.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) shares moved upwards by 33.1% ...
08-01 05:07
Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference
Cocrystal Pharma's first-in-class pan-viral protease inhibitor CDI-988, targeting norovirus and coronaviruses, will be presented at the 9th International Calicivirus Conference in September. The company highlights CDI-988's potential as an oral treatment against all norovirus strains, including GII.4 and GII.17. Phase 1 results and clinical strategy will be discussed by Dr. Sam Lee. CDI-988, developed using Cocrystal's structure-based platform, s...
07-10 12:00
美股大行评级 | 潜在涨幅378.93%！aTyr Pharma获富国银行升目标价至25美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1143101010774646784.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 富国银行：维持aTyr Pharma(ATYR)"超配"评级，目标价从17美元升至25美元</p> <p>• 摩根大通：维持Array Technologies(ARRY)"超配"评级，目标价从12美元升至13美元</p>
06-21 08:35
HC Wainwright & Co. Maintains Buy on Cocrystal Pharma, Lowers Price Target to $6
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cocrystal Pharma (NASDAQ:COCP) with a Buy and lowers the price target from $7 to $6.
06-20 19:16
Cocrystal Pharma’s CDI-988 Featured at Military Symposium
Cocrystal Pharma ( ($COCP) ) just unveiled an update. On June 5, 2025, Cocrysta...
06-06 03:47
Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference
Cocrystal Pharma's CDI-988, a broad-spectrum protease inhibitor for norovirus prevention and treatment, will be presented at the 2025 Military Health System Research Symposium. The compound targets viral replication, offering potential breakthroughs for norovirus outbreaks and demonstrating efficacy against coronaviruses. CDI-988's Phase 1 results and its novel mechanism were highlighted by the company as a transformative approach to antiviral th...
06-05 12:00
Cocrystal Pharma’s CC-42344 Shows Strong Antiviral Potency
Cocrystal Pharma ( ($COCP) ) just unveiled an update. Cocrystal Pharma announce...
05-29 20:57
Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain
<p>Cocrystal Pharma的新型抗病毒药物CC-42344在对抗高致病性2024 Texas H5N1禽流感病毒方面显示出显著效果，其效力较Tamiflu高出约1000倍。该药物通过抑制病毒PB2蛋白发挥作用，已进入临床开发阶段，初步数据显示其安全性和耐受性良好，为应对可能的流感大流行提供了新选择。!</p>
05-29 12:00
Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference
Cocrystal Pharma, Inc. announces its participation in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference on June 5, 2025. Management will engage in a fireside chat at 12:00 p.m. ET (9:00 a.m. PT), with investor registration available via the provided link. Qualified investors can schedule one-on-one meetings through the conference platform. A video webcast of the presentation will be available on Cocrystal's website and Channel...
05-28 12:00
Cocrystal Pharma Q1 EPS $(0.23) Beats $(0.51) Estimate
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.51) by 54.9 percent. This is a 41.03 percent increase over losses of $(0.39) per share from
05-15 20:18
